Mineralys Therapeutics (MLYS) Change in Interest Receivables (2023 - 2026)
Mineralys Therapeutics (MLYS) posted Change in Interest Receivables of -$289000.0 for Q1 2026, down 259.67% sequentially from $181000.0 in Q4 2025, and down 455.77% YoY from $81232.4 in Q1 2025.
Powered by 
Analysis
Mineralys Therapeutics (MLYS) Change in Interest Receivables (2023 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Change in Interest Receivables for 4 years, with the latest figure at -$289000.0 in Q1 2026.
- Quarterly Change in Interest Receivables fell 455.77% year-over-year to -$289000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$71000.0 (up 80.11% YoY) and the FY2025 annual result came in at $166000.0, up 139.15% from the prior year.
- Change in Interest Receivables fell to -$289000.0 in Q1 2026 per MLYS's latest filing, from $181000.0 in the prior quarter.
- Over five years, Change in Interest Receivables peaked at $270000.0 in Q1 2023 and troughed at -$300000.0 in Q4 2023.
- A 4-year average of -$14769.2 and a median of -$23000.0 in 2024 frame the typical range for Change in Interest Receivables.
- The sharpest annual moves came in 2025 and 2026: Change in Interest Receivables surged 284.69% in 2025, then slumped 455.77% in 2026.
- Over 4 years, Change in Interest Receivables stood at -$300000.0 in 2023, then jumped by 67.33% to -$98000.0 in 2024, then soared by 284.69% to $181000.0 in 2025, then sank by 259.67% to -$289000.0 in 2026.
- According to Business Quant data, Change in Interest Receivables over the past three periods registered -$289000.0, $181000.0, and -$10000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Mineralys Therapeutics | 2.39 Bn | 2.39 Bn | - | -47,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -47,000.00 |
| Mar 31, 2026 | -289,000.00 |
| Dec 31, 2025 | 181,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Jun 30, 2025 | 47,000.00 |
| Mar 31, 2025 | -52,000.00 |
| Dec 31, 2024 | -98,000.00 |
| Sep 30, 2024 | -23,000.00 |
| Jun 30, 2024 | -184,000.00 |
| Mar 31, 2024 | -119,000.00 |
| Dec 31, 2023 | -300,000.00 |
| Sep 30, 2023 | 219,000.00 |
| Jun 30, 2023 | 166,000.00 |
| Mar 31, 2023 | 270,000.00 |